Relative efficacy of oral cancer therapy for Medicare beneficiaries versus currently covered therapy: part 1, gefitinib and erlotinib for non-small cell lung cancer
Kelley MJ, McCrory DC
Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Citation
Kelley MJ, McCrory DC. Relative efficacy of oral cancer therapy for Medicare beneficiaries versus currently covered therapy: part 1, gefitinib and erlotinib for non-small cell lung cancer. Rockville: Agency for Healthcare Research and Quality (AHRQ). Technology Assessment. 2005
Authors' objectives
The aim of this review is to report on the relative efficacy of oral cancer therapy for Medicare beneficiaries versus currently covered therapy, in particular on gefitinib and erlotinib for non-small cell lung cancer.